PMV Pharmaceuticals' Q1 net loss widens

Pmv Pharmaceuticals

12/05/2026 13:11

Overview

US precision oncology firm's Q1 net loss widened to $18 mln, EPS at -0.34

Company's R&D and G&A expenses declined yr/yr due to lower research and personnel costs

Outlook

Company expects cash runway to end of Q2 2027

Result Drivers

R&D expenses were $15.3 million for the quarter ended March 31, 2026, compared to $17.4 million for the quarter ended March 31, 2025

General and administrative expenses were $3.7 million for the quarter ended March 31, 2026, compared to $4.1 million for the quarter ended March 31, 2025

Company press release: ID:nGNX9XVwRX

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.34
Q1 Net Income
-$18.04 mln
Q1 Operating Expenses
$19.02 mln
Q1 Operating Income
-$19.02 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for PMV Pharmaceuticals Inc is $4.50, about 223.7% above its May 11 closing price of $1.39

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)